Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Edwards Lifesciences

Edwards Lifesciences (NYSE: EW) insider transactions

In the twelve months to 10 November 2026, executives and directors of Edwards Lifesciences reported 55 open-market sales of 390,783 shares ($34.1m) and 0 open-market purchases, by 9 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Edwards Lifesciences shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
10 November 2026Lippis Daniel J.Cvp, TavrOption exercise, 10b5-1 plan+619$72.6840,653Form 4
10 November 2026Lippis Daniel J.Cvp, TavrOpen-market sale, 10b5-1 plan−619$104.2540,034Form 4
9 November 2026Bobo Donald E JRCVP,Strategy/Corp DevelopmentOption exercise, 10b5-1 plan+48,900$72.6871,698Form 4
9 November 2026Bobo Donald E JRCVP,Strategy/Corp DevelopmentOpen-market sale, 10b5-1 plan−48,900$103.0522,798Form 4
9 November 2026Zovighian Bernard JCEOOption exercise, 10b5-1 plan+23,100$72.68121,945Form 4
9 November 2026Zovighian Bernard JCEOOpen-market sale, 10b5-1 plan−9,184$103.39112,761Form 4
9 November 2026Zovighian Bernard JCEOOpen-market sale, 10b5-1 plan−13,916$102.7898,845Form 4
8 October 2026Lippis Daniel J.Cvp, TavrOption exercise, 10b5-1 plan+619$72.6840,653Form 4
8 October 2026Lippis Daniel J.Cvp, TavrOpen-market sale, 10b5-1 plan−619$85.6540,034Form 4
14 September 2026Markowitz WayneCvp, JapacShares withheld for tax−568$84.3719,371Form 4
13 September 2026Dahl Andrew M.SVP, Corporate ControllerShares withheld for tax−253$84.3714,615Form 4
11 September 2026Markowitz WayneCvp, JapacShares withheld for tax−355$86.7719,939Form 4
11 September 2026Lippis Daniel J.Cvp, TavrOption exercise, 10b5-1 plan+619$72.6840,653Form 4
11 September 2026Lippis Daniel J.Cvp, TavrOpen-market sale, 10b5-1 plan−619$87.5140,034Form 4
11 September 2026Chopra DaveenCVP, TMTT, Surgical & IHFMShares withheld for tax−398$86.7743,926Form 4
31 August 2026Dahl Andrew M.SVP, Corporate ControllerOpen-market sale−544$91.0614,868Form 4
28 August 2026Bruls AnnetteCvp, EmeaclaOpen-market sale−2,644$89.9817,984Form 4
26 August 2026Markowitz WayneCvp, JapacOpen-market sale−1,240$91.4720,294Form 4
26 August 2026Chopra DaveenCVP, TMTT, Surgical & IHFMOption exercise+31,800$72.6876,124Form 4
26 August 2026Chopra DaveenCVP, TMTT, Surgical & IHFMOpen-market sale−1,154$91.7674,970Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Edwards Lifesciences page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.